Z Squared Inc. quarterly report, Q1 FY2024

Filing summary: quarter ended March 31, 2024

Entity discrepancy: The request identifies Z Squared Inc., but the supplied Form 10-Q is for Coeptis Therapeutics Holdings, Inc. The figures and disclosures below summarize the supplied filing, not a filing identified as Z Squared’s.

Business context and reporting period

This unaudited quarterly report covers the three months ended March 31, 2024, with comparison to the same 2023 quarter. Coeptis is a development-stage biopharmaceutical company focused on cell-therapy technologies and related programs for cancer and other diseases. It reported no sales or consulting revenue in either quarter and says it does not expect significant revenue for at least two years.

Key financial metrics

MetricQ1 2024Q1 2023 / prior date
Revenue$0$0
Operating expenses$2.92 million$6.54 million
Operating loss$2.92 million$6.54 million
Net loss$3.00 million$7.96 million
Loss per share, basic and diluted$0.08$0.40
Net cash used in operating activities$1.90 million$1.68 million
Cash at period end$1.03 million$2.11 million at March 31, 2023
Total assets$9.39 million$8.07 million at December 31, 2023
Total liabilities$5.03 million$3.76 million at December 31, 2023

Gross margin is not meaningful because the company reported no revenue or cost of goods. Current assets were $6.88 million, including $5.50 million of notes receivable; current liabilities were $4.30 million. Notes payable totaled $2.34 million, of which $2.19 million was classified as current. The company had an accumulated deficit of $90.36 million.

Material changes versus the prior comparable period

  • Operating expenses fell by $3.62 million, primarily because professional-services expense related to equity transactions was lower. Professional-services expense declined from $5.55 million to $1.18 million.
  • Research and development expense increased from $115,329 to $777,069; salary expense rose from $283,917 to $445,359.
  • Net loss improved by $4.96 million, partly reflecting lower operating costs and a much smaller warrant fair-value loss/benefit effect than in 2023. Interest expense increased to $200,505 from $31,417.
  • Operating cash use increased by $217,920 year over year. Cash declined $439,890 during Q1 2024, after $1.56 million of net financing cash inflows and $100,000 of investing cash outflow.
  • Common shares outstanding increased to 36.43 million at quarter-end from 35.33 million at year-end 2023. The filing reports 37,118,593 shares outstanding as of May 8, 2024.

Outlook, risks, contingencies, and unusual items

  • Going concern: Management says the accumulated deficit and Q1 net loss raise substantial doubt about the company’s ability to continue as a going concern. It plans to seek additional equity or debt financing, but gives no assurance it can obtain funding or achieve profitability.
  • Defaults and debt: At March 31, the $437,500 Purple convertible note and $100,000 legal-services convertible note were in default. The $1.50 million January 2024 borrowing, originally extended to April 15, 2024, was also reported in default as of the filing date. The filing describes other near-term debt obligations and repayments. A $150,000 note was converted into common shares on April 24; on April 17, the company borrowed another $500,000 at 10% interest from a fund whose manager is a board member.
  • Financing and dilution: Q1 financing included $1.35 million of note proceeds and $500,000 from shares issued for cash. The company also issued 4.0 million pre-funded warrants in February, alongside a $1.90 million note receivable. Total warrants outstanding were reported as 16.70 million at March 31.
  • Receivables: Notes receivable increased to $5.50 million, including substantial third-party loans bearing 6% interest and maturing in 2024. Collection and timing of these receivables are important to liquidity; the filing does not establish that they are available as cash.
  • Development outlook: The company is pursuing GEAR-NK/CD38 programs, SNAP-CAR and Deverra-related cell-therapy assets. It says development costs may increase. It has deprioritized CPT60621 and is negotiating a possible buyout of most or all of its remaining rights.
  • Contingencies: The filing reports no material litigation or threatened litigation. Certain licenses and sublicenses include potential milestone and royalty payments tied to future development or commercialization.
  • Reporting controls: Management concluded disclosure controls and procedures were not effective as of March 31, 2024, citing self-identified material weaknesses, including ineffective internal controls and financial-statement close processes.

Most important facts for investors to verify

  • Confirm the issuer: the supplied filing is Coeptis Therapeutics Holdings, Inc., not Z Squared Inc.
  • Check subsequent filings for the status, amount, and resolution of the disclosed debt defaults and the April related-party borrowing.
  • Assess collection timing and credit risk for the $5.50 million of notes receivable, including related financing arrangements and warrant consideration.
  • Review cash runway, financing availability, and dilution from outstanding warrants and further capital raises in light of the going-concern disclosure.
  • Track remediation of the disclosed material weaknesses and progress toward meaningful revenue, clinical development, and partnership milestones.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.